Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares saw an uptick in trading volume on Friday . 62,552 shares traded hands during mid-day trading, an increase of 81% from the previous session’s volume of 34,487 shares.The stock last traded at $19.61 and had previously closed at $19.67.

Analysts Set New Price Targets

NBTX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Tuesday. Leerink Partners set a $14.00 price objective on Nanobiotix in a report on Thursday, September 18th. Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Nanobiotix currently has a consensus rating of “Hold” and an average price target of $11.00.

Nanobiotix Stock Performance

The company has a 50 day moving average of $17.22 and a 200-day moving average of $9.43.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.